R-2487 in Patients With Rheumatoid Arthritis
NCT05961592
This study is recruiting at 6 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Arthritis, Rheumatoid
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Rise Therapeutics LLC
- Last updated on ClinicalTrials.gov
- June 12, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California, San Diego · San Diego, CA
Florida · 3
- St.Jude Clinical Research · Doral, FL
- AP Medical Research · Miami, FL
- Edward Jenner Research · Plantation, FL
Pennsylvania · 1
- Altoona Center for Research · Duncansville, PA
Texas · 1
- Prolato Clinical Research Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.